Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nilotinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Aurobindo Pharma Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Aurobindo Pharma Arm Signs Pact with Medicines Patent Pool to Develop Anti-Cancer Drug
Details : The agreement aims to to develop and market an anti-cancer drug, Tasigna (nilotinib), a transduction inhibitor, used for treatment of chronic myeloid leukemia.
Product Name : Tasigna-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 23, 2023
Lead Product(s) : Nilotinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Aurobindo Pharma Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Aurobindo Pharma Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Med Patent Pool Signs with Aurobindo, Cipla & Viatris for Generic HIV Prevention Medicine
Details : ViiV Healthcare sublicence agreements with Aurobindo, Cipla and Viatris to manufacture generic versions of cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis.
Product Name : Apretude-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Aurobindo Pharma Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : ViiV Healthcare
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Through the agreement, the selected generic manufacturers, Aurobindo, Cipla and Viatris, will be able to develop, manufacture, and supply generic versions of cabotegravir LA for PrEP, in 90 countries, subject to required regulatory approvals being obtain...
Product Name : Cabotegravir-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : ViiV Healthcare
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : MedinCell
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : This non-exclusive licence agreement, will enable MPP to support the identification of suitable partners for the development and commercialisation of mdc-STM, an injectable formulation of ivermectin with a three-month action-duration.
Product Name : mdc-STM
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 13, 2022
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : MedinCell
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : ViiV Healthcare
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Through this agreement, selected generic manufacturers will have the opportunity to develop, manufacture and supply generic versions of cabotegravir LA for PrEP, the first long-acting HIV prevention medicine, in 90 countries, subject to regulatory approv...
Product Name : Cabotegravir LA-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 28, 2022
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : ViiV Healthcare
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Recipient : Nortec Quimica
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : With this agreement, the active pharmaceutical ingredient nirmatrelvir can be fully manufactured in Brazil by Nortec, ensuring safety and adherence to treatment for countries such as: South Africa, Tanzania, Venezuela, Bolivia, Ethiopia, Haiti, Honduras,...
Product Name : Nirmatrelvir-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 22, 2022
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Recipient : Nortec Quimica
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Strides Pharma Science
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement aims to commercialize a generic version of Pfizer’s COVID-19 oral treatment, Paxlovid (nirmatrelvir and ritonavir), indicated for the treatment of mild-to-moderate coronavirus disease, in 95 low and middle-income markets.
Product Name : Nirmatrelvir-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 21, 2022
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Strides Pharma Science
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Details : Sublicences will allow manufacturers (Teva, Cipla, Biocon, Amneal, Viatris, Torrent, MSN, Sun Pharma, Cadila, Glenmark, Fosun, Beximco, Celltrion & others) to produce the raw materials for generic of Pfizer’s COVID-19 nirmatrelvir and finished drug co-...
Product Name : Nirmatrelvir-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 17, 2022
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Strides Pharma Science
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, Strides and UCL will manufacture Stripiravir (molnupiravir), an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS‐CoV‐2, in India and Nairobi, Kenya.
Product Name : Stripiravir
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 20, 2022
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Strides Pharma Science
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Biophore India Pharmaceuticals Pvt Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Biophore Receives Sub-License From MPP to Manufacture and Market Molnupiravir for Covid Treatment
Details : The licences are applicable for both molnupiravir (API) and finished product in capsules form. It enables the company to launch the product within India as well as export to 104 other countries around the world, Biophore India Pharmaceuticals said in a s...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 20, 2022
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Biophore India Pharmaceuticals Pvt Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement